Marinko Marušić

Marinko Marušić

Auto-generated profile, based on publicly available information

Marinko Marušić

University Hospital Sveti Duh

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
MMMarinko Marušić
Marinko Marušić
MPmatej paić
matej paić
MKMia Knobloch
Mia Knobloch
APAna-Marija Liberati Pršo
Ana-Marija Liberati Pršo
Nonalcoholic fatty liver disease is a condition defined by fat accumulation in hepatocytes not promoted by excessive alcohol consumption. It is highly prevalent and is strongly associated with insulin resistance, metabolic syndrome, and diabetes type II. Insulin resistance plays a crucial role in the multifactorial etiopathogenesis of this condition leading to accumulation of free fatty acids in the liver cells, thus causing lipotoxicity, inflammation, and fibrosis. In this review, we will focus on currently known pathogenesis of nonalcoholic fatty liver disease. Numerous investigation strategies are available to establish the diagnosis, from biochemical markers and ultrasound to various molecular and advanced imaging techniques and liver biopsy. Prevention is crucial. However, effective and promising therapies are strongly demanded.

2 March 2017 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
KLKrešimir Luetic
Krešimir Luetic
MSMario Sucic
Mario Sucic
JVJosipa Vlainic
Josipa Vlainic
ZHZeljka Belosic Halle
Zeljka Belosic Halle
DSDean Strinic
Dean Strinic
PSPredrag Sikiric
Predrag Sikiric

1 June 2007 in Wiener klinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
PBPetra Bago
Petra Bago
AVAleksandar Vcev
Aleksandar Vcev
MTMonika Tomic
Monika Tomic
MRMarjan Rožankovic
Marjan Rožankovic
MMMarinko Marušić
Marinko Marušić
JBJosip Bago
Josip Bago

1 January 2009 in Wiener klinische Wochenschrift
Verified
Journal Article
Open access
PDF file
JBJosip Bago
Josip Bago
BPBranko Pevec
Branko Pevec
MTMonika Tomić
Monika Tomić
MMMarinko Marušić
Marinko Marušić
VBVinko Bakula
Vinko Bakula
PBPetra Bago
Petra Bago
BACKGROUND: In eradication of Helicobacter pylori infection, standard quadruple second-line therapy consisting of proton pump inhibitor (PPI), bismuth, metronidazole and tetracycline often fails and shows poor patient compliance. The aim of our study was to evaluate the efficacy and tolerability of moxifloxacin-based triple therapy as an alternative second-line protocol. METHODS: A total of 160 patients, in whom the initial standard PPI triple therapy had failed to eradicate H. pylori infection, were included in the study. The initial H. pylori status was assessed using the ^13C-urea breath test. Patients were randomized to one of the following 7-day treatment regimens: (1) OMM: omeprazole 20 mg twice a day, moxifloxacin 400 mg/day, metronidazole 500 mg three times a day; and (2) OBMT: omeprazole 20 mg twice a day, colloidal bismuth subcitrate 120 mg four times a day, metronidazole 500 mg three times a day, tetracycline 500 mg four times a day. Patient compliance and adverse events were evaluated one week after completion of therapy. H. pylori status was re-assessed with the ^13C-urea breath test six weeks after the end of therapy. RESULTS: The eradication rates were 73.2% (60/82) and 78.9% (60/76) with moxifloxacin-based triple therapy, and 53.8% (42/78) and 64.6% (42/65) with bismuth-based quadruple therapy, by intention-to-treat ( p = 0.018) and per-protocol ( p = 0.088) analyses, respectively. Adverse events/intolerability were described in 12/82 patients in the OMM group and 18/78 patients in the OBMT group. Compliance with treatment was 92.7% in the OMM group and 83.3% in the OBMT group. CONCLUSION: Moxifloxacin-based triple therapy is a highly effective second-line eradication treatment in H. pylori infection. Because of its high levels of safety and tolerability, this protocol represents an adequate alternative to the standard bismuth-based quadruple therapy. HINTERGRUND DER STUDIE: Die Standard-Quadruple-Second-Line-Therapie zur Eradikation einer Helicobacter pylori (Hp) Infektion, bestehend aus einem Protonenpumpen-Hemmer (PPI), Bismuth, Metronidazol und Tetracyclin versagt häufig, wobei die Patienten oft eine schlechte Compliance bei dieser Therapie zeigen. Ziel der vorliegenden Studie war es, die Wirksamkeit und Verträglichkeit einer Moxifloxacin-basierten Triple Therapie als alternatives Second-Line-Protokoll zu untersuchen. METHODEN: 160 Patienten, bei denen die initiale Standard PPI-Triple-Therapie zur Eradikation einer Infektion mit Hp versagt hatte, wurden in die Studie aufgenommen. Der ursprüngliche Hp-Status wurde durch den C13-Urea-Atemtest erhoben. Die Patienten wurden zu folgenden 7-Tages Therapieschemata randomisiert: 1) "OMM": Omeprazol 20 mg 2 × tgl., Moxifloxacin 400 mg/Tag, Metronidazol 500 mg 3 × tgl; 2) "OBMT": Omeprazol 20 mg 2 × tgl., kolloidales Bismuth Subzitrat 120 mg 4 × tgl., Metronidazol 500 mg 3 × tgl., Tetrazyklin 500 mg 4 × tgl. Eine Woche nach Ende der Therapie wurde durch Pillenzählen die Compliance überprüft und nach Nebenwirkungen gefragt. Der Hp-Status wurde durch den C13-Urea-Atemtest 6 Wochen nach Ende der Therapie reevaluiert. ERGEBNISSE: Folgende Eradikationsraten wurden erhoben: Für die mit dem OMM-Schema behandelten Patienten: 73,2% (60/82 – intention to treat) bzw. 78,9% (60/76 per-Protokoll-Analyse). Für die mit dem OBMT-Schema behandelten Patienten: 53,8% (42/78 intention to treat; p = 0.018 im Vergleich zu OMM) bzw. 64,6% (42/65 per Protokoll, p = 0.088 im Vergleich zu OMM). Nebenwirkungen und/oder Unverträglichkeit wurden von 12 der 82 OMM Patienten bzw. von 18 der 78 OBMT Patienten angegeben. Die Compliance betrug 92,7% in der OMM Gruppe und 83,3% in der OBMT Gruppe. SCHLUSSFOLGERUNGEN: Die Moxifloxacin-basierte Triple-Therapie ist eine sehr wirksame second-line Behandlung zur Eradikation einer Hp Infektion. Auf Grund der hochgradigen Sicherheit und guten Verträglichkeit stellt dieses Protokoll eine adäquate Alternative zur bisherigen Bismuth-basierten Standard-Therapie dar.

14 July 2021 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
NMNikolina Marić
Nikolina Marić
MMMaja Mačković
Maja Mačković
MBMiro Bakula
Miro Bakula
KMKatarina Mucić
Katarina Mucić
NUNikola Udiljak
Nikola Udiljak
MMMarinko Marušić
Marinko Marušić

1 January 2012
Verified
Book Chapter
Closed access
PDF file
PSPavle Skočir
Pavle Skočir
LMLuka Marusic
Luka Marusic
MMMarinko Marusic
Marinko Marusic
APAna Petric
Ana Petric